Absence of amyloid β oligomers at the postsynapse and regulated synaptic Zn2+ in cognitively intact aged individuals with Alzheimer’s disease neuropathology

Background Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline despite the presence of the neuropathologic features of AD (Aβ plaques and neu...

Full description

Saved in:
Bibliographic Details
Published inMolecular neurodegeneration Vol. 7; no. 1; p. 23
Main Authors Bjorklund, Nicole L, Reese, Lindsay C, Sadagoparamanujam, V-M, Ghirardi, Valeria, Woltjer, Randall L, Taglialatela, Giulio
Format Journal Article
LanguageEnglish
Published London BioMed Central 28.05.2012
BMC
Subjects
Online AccessGet full text
ISSN1750-1326
1750-1326
DOI10.1186/1750-1326-7-23

Cover

Abstract Background Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline despite the presence of the neuropathologic features of AD (Aβ plaques and neurofibrillary tangles). We term this group Non-Demented with AD Neuropathology or NDAN. The present study illustrates one putative resistance mechanism involved in NDAN cases which may suggest targets for the effective treatment of AD. Results Here we describe the localization of Aβ oligomers at the postsynapse in hippocampi from AD cases. Notably, however, we also found that while present in soluble fractions, Aβ oligomers are absent from hippocampal postsynapses in NDAN cases. In addition, levels of phosphorylated (active) CREB, a transcription factor important for synaptic plasticity, are normal in NDAN individuals, suggesting that their synapses are functionally intact. Analysis of Zn 2+ showed that levels were increased in both soluble fractions and synaptic vesicles in AD hippocampi, paralleled by a decrease of expression of the synaptic vesicle Zn 2+ transporter, ZnT3. Conversely, in NDAN individuals, levels of Zn 2+ in soluble fractions were significantly lower than in AD, whereas in synaptic vesicles the levels of Zn 2+ were similar to AD, but accompanied by preserved expression of the ZnT3. Conclusions Taken together, these data illustrate that despite substantial AD neuropathology, Aβ oligomers, and increased synaptic vesicle Zn 2+ , susceptible brain tissue in these aged NDAN individuals features, as compared to symptomatic AD subjects, significantly lower total Zn 2+ levels and no association of Aβ oligomers with the postsynapse, which collectively may promote the maintenance of intact cognitive function.
AbstractList Background Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline despite the presence of the neuropathologic features of AD (Aβ plaques and neurofibrillary tangles). We term this group Non-Demented with AD Neuropathology or NDAN. The present study illustrates one putative resistance mechanism involved in NDAN cases which may suggest targets for the effective treatment of AD. Results Here we describe the localization of Aβ oligomers at the postsynapse in hippocampi from AD cases. Notably, however, we also found that while present in soluble fractions, Aβ oligomers are absent from hippocampal postsynapses in NDAN cases. In addition, levels of phosphorylated (active) CREB, a transcription factor important for synaptic plasticity, are normal in NDAN individuals, suggesting that their synapses are functionally intact. Analysis of Zn 2+ showed that levels were increased in both soluble fractions and synaptic vesicles in AD hippocampi, paralleled by a decrease of expression of the synaptic vesicle Zn 2+ transporter, ZnT3. Conversely, in NDAN individuals, levels of Zn 2+ in soluble fractions were significantly lower than in AD, whereas in synaptic vesicles the levels of Zn 2+ were similar to AD, but accompanied by preserved expression of the ZnT3. Conclusions Taken together, these data illustrate that despite substantial AD neuropathology, Aβ oligomers, and increased synaptic vesicle Zn 2+ , susceptible brain tissue in these aged NDAN individuals features, as compared to symptomatic AD subjects, significantly lower total Zn 2+ levels and no association of Aβ oligomers with the postsynapse, which collectively may promote the maintenance of intact cognitive function.
Abstract Background Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline despite the presence of the neuropathologic features of AD (Aβ plaques and neurofibrillary tangles). We term this group Non-Demented with AD Neuropathology or NDAN. The present study illustrates one putative resistance mechanism involved in NDAN cases which may suggest targets for the effective treatment of AD. Results Here we describe the localization of Aβ oligomers at the postsynapse in hippocampi from AD cases. Notably, however, we also found that while present in soluble fractions, Aβ oligomers are absent from hippocampal postsynapses in NDAN cases. In addition, levels of phosphorylated (active) CREB, a transcription factor important for synaptic plasticity, are normal in NDAN individuals, suggesting that their synapses are functionally intact. Analysis of Zn2+ showed that levels were increased in both soluble fractions and synaptic vesicles in AD hippocampi, paralleled by a decrease of expression of the synaptic vesicle Zn2+ transporter, ZnT3. Conversely, in NDAN individuals, levels of Zn2+ in soluble fractions were significantly lower than in AD, whereas in synaptic vesicles the levels of Zn2+ were similar to AD, but accompanied by preserved expression of the ZnT3. Conclusions Taken together, these data illustrate that despite substantial AD neuropathology, Aβ oligomers, and increased synaptic vesicle Zn2+, susceptible brain tissue in these aged NDAN individuals features, as compared to symptomatic AD subjects, significantly lower total Zn2+ levels and no association of Aβ oligomers with the postsynapse, which collectively may promote the maintenance of intact cognitive function.
Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline despite the presence of the neuropathologic features of AD (Aβ plaques and neurofibrillary tangles). We term this group Non-Demented with AD Neuropathology or NDAN. The present study illustrates one putative resistance mechanism involved in NDAN cases which may suggest targets for the effective treatment of AD. Here we describe the localization of Aβ oligomers at the postsynapse in hippocampi from AD cases. Notably, however, we also found that while present in soluble fractions, Aβ oligomers are absent from hippocampal postsynapses in NDAN cases. In addition, levels of phosphorylated (active) CREB, a transcription factor important for synaptic plasticity, are normal in NDAN individuals, suggesting that their synapses are functionally intact. Analysis of Zn2+ showed that levels were increased in both soluble fractions and synaptic vesicles in AD hippocampi, paralleled by a decrease of expression of the synaptic vesicle Zn2+ transporter, ZnT3. Conversely, in NDAN individuals, levels of Zn2+ in soluble fractions were significantly lower than in AD, whereas in synaptic vesicles the levels of Zn2+ were similar to AD, but accompanied by preserved expression of the ZnT3. Taken together, these data illustrate that despite substantial AD neuropathology, Aβ oligomers, and increased synaptic vesicle Zn2+, susceptible brain tissue in these aged NDAN individuals features, as compared to symptomatic AD subjects, significantly lower total Zn2+ levels and no association of Aβ oligomers with the postsynapse, which collectively may promote the maintenance of intact cognitive function.
Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline despite the presence of the neuropathologic features of AD (Aβ plaques and neurofibrillary tangles). We term this group Non-Demented with AD Neuropathology or NDAN. The present study illustrates one putative resistance mechanism involved in NDAN cases which may suggest targets for the effective treatment of AD.BACKGROUNDEarly cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline despite the presence of the neuropathologic features of AD (Aβ plaques and neurofibrillary tangles). We term this group Non-Demented with AD Neuropathology or NDAN. The present study illustrates one putative resistance mechanism involved in NDAN cases which may suggest targets for the effective treatment of AD.Here we describe the localization of Aβ oligomers at the postsynapse in hippocampi from AD cases. Notably, however, we also found that while present in soluble fractions, Aβ oligomers are absent from hippocampal postsynapses in NDAN cases. In addition, levels of phosphorylated (active) CREB, a transcription factor important for synaptic plasticity, are normal in NDAN individuals, suggesting that their synapses are functionally intact. Analysis of Zn2+ showed that levels were increased in both soluble fractions and synaptic vesicles in AD hippocampi, paralleled by a decrease of expression of the synaptic vesicle Zn2+ transporter, ZnT3. Conversely, in NDAN individuals, levels of Zn2+ in soluble fractions were significantly lower than in AD, whereas in synaptic vesicles the levels of Zn2+ were similar to AD, but accompanied by preserved expression of the ZnT3.RESULTSHere we describe the localization of Aβ oligomers at the postsynapse in hippocampi from AD cases. Notably, however, we also found that while present in soluble fractions, Aβ oligomers are absent from hippocampal postsynapses in NDAN cases. In addition, levels of phosphorylated (active) CREB, a transcription factor important for synaptic plasticity, are normal in NDAN individuals, suggesting that their synapses are functionally intact. Analysis of Zn2+ showed that levels were increased in both soluble fractions and synaptic vesicles in AD hippocampi, paralleled by a decrease of expression of the synaptic vesicle Zn2+ transporter, ZnT3. Conversely, in NDAN individuals, levels of Zn2+ in soluble fractions were significantly lower than in AD, whereas in synaptic vesicles the levels of Zn2+ were similar to AD, but accompanied by preserved expression of the ZnT3.Taken together, these data illustrate that despite substantial AD neuropathology, Aβ oligomers, and increased synaptic vesicle Zn2+, susceptible brain tissue in these aged NDAN individuals features, as compared to symptomatic AD subjects, significantly lower total Zn2+ levels and no association of Aβ oligomers with the postsynapse, which collectively may promote the maintenance of intact cognitive function.CONCLUSIONSTaken together, these data illustrate that despite substantial AD neuropathology, Aβ oligomers, and increased synaptic vesicle Zn2+, susceptible brain tissue in these aged NDAN individuals features, as compared to symptomatic AD subjects, significantly lower total Zn2+ levels and no association of Aβ oligomers with the postsynapse, which collectively may promote the maintenance of intact cognitive function.
ArticleNumber 23
Author Reese, Lindsay C
Sadagoparamanujam, V-M
Woltjer, Randall L
Bjorklund, Nicole L
Ghirardi, Valeria
Taglialatela, Giulio
AuthorAffiliation 1 Department of Neuroscience and Cell Biology, Galveston, TX, 77555, USA
3 Department of Pathology, Oregon Health & Science University, Portland, OR, 97201, USA
2 Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX, 77555, USA
AuthorAffiliation_xml – name: 1 Department of Neuroscience and Cell Biology, Galveston, TX, 77555, USA
– name: 2 Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX, 77555, USA
– name: 3 Department of Pathology, Oregon Health & Science University, Portland, OR, 97201, USA
Author_xml – sequence: 1
  givenname: Nicole L
  surname: Bjorklund
  fullname: Bjorklund, Nicole L
  organization: Department of Neuroscience and Cell Biology
– sequence: 2
  givenname: Lindsay C
  surname: Reese
  fullname: Reese, Lindsay C
  organization: Department of Neuroscience and Cell Biology
– sequence: 3
  givenname: V-M
  surname: Sadagoparamanujam
  fullname: Sadagoparamanujam, V-M
  organization: Department of Preventive Medicine and Community Health, University of Texas Medical Branch
– sequence: 4
  givenname: Valeria
  surname: Ghirardi
  fullname: Ghirardi, Valeria
  organization: Department of Neuroscience and Cell Biology
– sequence: 5
  givenname: Randall L
  surname: Woltjer
  fullname: Woltjer, Randall L
  organization: Department of Pathology, Oregon Health & Science University
– sequence: 6
  givenname: Giulio
  surname: Taglialatela
  fullname: Taglialatela, Giulio
  email: gtaglial@utmb.edu
  organization: Department of Neuroscience and Cell Biology
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22640423$$D View this record in MEDLINE/PubMed
BookMark eNp1ks1uEzEQx1eoiH7AlSPyEQlt64_d7OaCFFV8VKrEBS5crFl7duPIsYPtDQqnvkZPvAMPwkPwJDhJiVqknmzP_P-_8WjmtDhy3mFRvGT0nLF2csGampZM8EnZlFw8KU4OgaN79-PiNMYFpVVDaf2sOOZ8UtGKi5Pi56yL6BQS3xNYbqw3mvz-Rbw1g19iiAQSSXMkKx9T3DhYRSTgNAk4jBYSarKLJqPIV8ffEOOI8oMzyazRbvIzgUoEhiw0Tpu10SPYSL6bNCcz-2OOJlf5c3MbiTYRIdMdjsGvIM299cPmefG0zwZ8cXeeFV_ev_t8-bG8_vTh6nJ2XaqKT1IpaEt53WAHDHoquOaCTlvW0j5336DqaNv2IABUTau60VUltEbWNXXfY06Is-Jqz9UeFnIVzBLCRnowchfwYZAQcpcWZV2rBoDSTnS8Uoy3DCvaCtogqF6LOrPe7lmrsVuiVuhSAPsA-jDjzFwOfi1FRcW03QJe3wGC_zZiTHJpokJrwaEfo2SUt5Q1k3aapa_u1zoU-TfhLDjfC1TwMQbsDxJG5XaF5HZL5HZLZCN3huo_gzIJkvHbvxr7uO1ib4uZ7wYMcuHH4PLMHnP8BRjF3cY
CitedBy_id crossref_primary_10_3389_fncel_2021_660693
crossref_primary_10_1007_s00401_022_02526_0
crossref_primary_10_1001_jamaneurol_2023_3530
crossref_primary_10_1017_neu_2015_18
crossref_primary_10_1172_JCI64595
crossref_primary_10_1016_j_semcdb_2022_05_028
crossref_primary_10_1038_srep36772
crossref_primary_10_1038_s41582_022_00642_9
crossref_primary_10_3233_JAD_180179
crossref_primary_10_3389_fphar_2014_00085
crossref_primary_10_3389_fneur_2022_882635
crossref_primary_10_1038_s41598_017_15357_x
crossref_primary_10_2139_ssrn_4200166
crossref_primary_10_1093_mtomcs_mfae053
crossref_primary_10_1111_jnc_13713
crossref_primary_10_3389_fncel_2015_00191
crossref_primary_10_3390_biomedicines10071743
crossref_primary_10_9729_AM_2012_42_4_200
crossref_primary_10_1007_s12035_020_01868_8
crossref_primary_10_1002_jnr_23777
crossref_primary_10_1111_jnc_13043
crossref_primary_10_3233_JAD_200716
crossref_primary_10_1016_j_cca_2017_11_009
crossref_primary_10_1007_s12263_013_0379_x
crossref_primary_10_1016_j_neubiorev_2023_105246
crossref_primary_10_1016_j_pharmthera_2023_108398
crossref_primary_10_1038_s41467_021_22742_8
crossref_primary_10_1016_j_pneurobio_2015_03_003
crossref_primary_10_3389_fnmol_2022_1016559
crossref_primary_10_1111_bpa_13108
crossref_primary_10_1186_s13024_024_00719_7
crossref_primary_10_1007_s00018_020_03473_3
crossref_primary_10_1007_s11095_017_2267_3
crossref_primary_10_1016_j_pneurobio_2017_03_001
crossref_primary_10_1016_j_phymed_2025_156366
crossref_primary_10_1016_j_neubiorev_2017_06_006
crossref_primary_10_1038_s42003_023_05511_9
crossref_primary_10_1038_s41392_023_01679_y
crossref_primary_10_1038_srep38187
crossref_primary_10_3390_jcm8050685
crossref_primary_10_1111_acel_12802
crossref_primary_10_1016_j_arr_2025_102711
crossref_primary_10_3389_fnins_2018_00037
crossref_primary_10_1038_s41380_022_01459_0
crossref_primary_10_1016_j_neurobiolaging_2014_06_015
crossref_primary_10_1038_s41598_024_66970_6
crossref_primary_10_1523_JNEUROSCI_0295_20_2020
crossref_primary_10_1523_JNEUROSCI_3307_17_2018
crossref_primary_10_1007_s10072_015_2352_5
crossref_primary_10_3233_JAD_210607
crossref_primary_10_3389_fnins_2024_1420322
crossref_primary_10_3389_fnagi_2014_00174
crossref_primary_10_1038_srep27812
crossref_primary_10_2337_db13_1954
crossref_primary_10_1016_j_ajpath_2015_09_018
crossref_primary_10_1152_physrev_00035_2014
crossref_primary_10_1155_2015_591563
crossref_primary_10_1016_j_celrep_2020_107900
crossref_primary_10_1093_brain_awab319
crossref_primary_10_1039_C4CS00138A
crossref_primary_10_1371_journal_pone_0259335
crossref_primary_10_3389_fncel_2015_00464
crossref_primary_10_2139_ssrn_3519898
crossref_primary_10_3233_JAD_150065
crossref_primary_10_1007_s00401_024_02775_1
crossref_primary_10_1016_j_ebiom_2016_03_035
Cites_doi 10.1523/JNEUROSCI.3432-04.2004
10.1016/S0143-4160(03)00140-4
10.1186/1750-1326-4-53
10.1212/WNL.54.1.105
10.1523/JNEUROSCI.3501-06.2007
10.1007/s00418-005-0787-0
10.1177/002215549904700211
10.1074/jbc.R600011200
10.1146/annurev.neuro.21.1.127
10.1016/S0006-8993(00)03196-6
10.1111/j.1471-4159.2006.04157.x
10.1021/ja076282l
10.1016/j.neurobiolaging.2010.01.010
10.1016/0022-3956(75)90026-6
10.1016/j.neurobiolaging.2007.05.005
10.1113/jphysiol.2005.103754
10.1111/j.1471-4159.2010.06643.x
10.1016/j.pharmthera.2005.11.004
10.1016/j.bbr.2008.06.001
10.1016/0028-3908(94)90152-X
10.1212/01.wnl.0000223644.08653.b5
10.1093/jn/130.5.1471S
10.1007/BF02796647
10.1523/JNEUROSCI.5980-08.2009
10.1096/fj.04-2370com
10.1007/BF00308809
10.1016/S0002-9440(10)65184-X
10.1126/science.1074069
10.1074/jbc.M100175200
10.1016/S0021-9258(17)32694-7
10.1016/j.bpj.2011.02.042
10.1097/NEN.0b013e3181772794
10.1038/nm1782
10.1002/syn.20683
10.1007/s00401-011-0910-3
10.1038/nature04533
10.1016/S0165-0270(97)00079-4
10.3233/JAD-2009-0992
10.1021/bi701112z
10.1073/pnas.0811698106
10.1074/jbc.271.24.14214
10.1523/JNEUROSCI.5255-09.2010
10.1212/WNL.41.4.479
10.1016/0896-6273(91)90272-2
10.1186/1750-1326-6-65
10.1093/jn/130.5.1484S
10.1126/science.8073293
10.1016/S0006-8993(99)02096-X
10.1038/308734a0
10.1002/jnr.22445
10.1016/S0896-6273(01)00450-0
10.1016/j.jneumeth.2008.05.003
10.4061/2011/971021
10.1074/jbc.M500997200
10.1016/S0022-510X(96)00203-1
10.1021/bi047611e
10.1016/j.jneumeth.2011.09.008
10.1111/j.1474-9726.2008.00434.x
10.1523/JNEUROSCI.1064-09.2009
10.3390/s8117428
10.1038/nn1372
10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M
10.1212/01.wnl.0000341273.18141.64
10.1073/pnas.91.18.8378
10.1021/bi990205o
10.1016/0165-6147(91)90609-V
ContentType Journal Article
Copyright Bjorklund et al.; licensee BioMed Central Ltd 2012 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright ©2012 Bjorklund et al.; licensee BioMed Central Ltd 2012 Bjorklund et al.; licensee BioMed Central Ltd
Copyright_xml – notice: Bjorklund et al.; licensee BioMed Central Ltd 2012 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
– notice: Copyright ©2012 Bjorklund et al.; licensee BioMed Central Ltd 2012 Bjorklund et al.; licensee BioMed Central Ltd
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1186/1750-1326-7-23
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals (Selected full-text)
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1750-1326
EndPage 23
ExternalDocumentID oai_doaj_org_article_55c7aa00b3b24c1281e408307eacfd35
PMC3403985
22640423
10_1186_1750_1326_7_23
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NINDS NIH HHS
  grantid: F31NS062558
– fundername: NINDS NIH HHS
  grantid: R01NS059901
– fundername: NIEHS NIH HHS
  grantid: T32 ES007254-20
– fundername: NIA NIH HHS
  grantid: P30AG008017
GroupedDBID ---
0R~
123
29M
2VQ
2WC
4.4
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABIVO
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IHR
INH
INR
IPNFZ
IPY
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RIG
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
~8M
AAYXX
ALIPV
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c426t-3080257eba1af032d23098180f3267ecb088fa3aac50457d443dde1b75ffefa33
IEDL.DBID M48
ISSN 1750-1326
IngestDate Wed Aug 27 01:32:51 EDT 2025
Thu Aug 21 18:33:59 EDT 2025
Thu Sep 04 16:41:00 EDT 2025
Thu Apr 03 07:00:57 EDT 2025
Tue Jul 01 01:59:01 EDT 2025
Thu Apr 24 22:51:17 EDT 2025
Sat Sep 06 07:29:28 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Alzheimer’s disease
hippocampus
asymptomatic, zinc, synaptic vesicle
Aβ oligomers
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c426t-3080257eba1af032d23098180f3267ecb088fa3aac50457d443dde1b75ffefa33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/55c7aa00b3b24c1281e408307eacfd35
PMID 22640423
PQID 1028017689
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_55c7aa00b3b24c1281e408307eacfd35
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3403985
proquest_miscellaneous_1028017689
pubmed_primary_22640423
crossref_primary_10_1186_1750_1326_7_23
crossref_citationtrail_10_1186_1750_1326_7_23
springer_journals_10_1186_1750_1326_7_23
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-05-28
PublicationDateYYYYMMDD 2012-05-28
PublicationDate_xml – month: 05
  year: 2012
  text: 2012-05-28
  day: 28
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Molecular neurodegeneration
PublicationTitleAbbrev Mol Neurodegeneration
PublicationTitleAlternate Mol Neurodegener
PublicationYear 2012
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References S Lesne (334_CR10) 2006; 440
AG Henriques (334_CR64) 2010; 113
SA Amico-Ruvio (334_CR37) 2011; 100
CJ Frederickson (334_CR55) 2000; 130
GM Aldridge (334_CR66) 2008; 172
HM Abdul (334_CR21) 2009; 29
D Erten-Lyons (334_CR6) 2009; 72
LC Reese (334_CR12) 2008; 7
M Stoltenberg (334_CR58) 2005; 123
SS Mirra (334_CR60) 1991; 41
GM Shankar (334_CR20) 2008; 14
A Mathie (334_CR39) 2006; 111
WH Yu (334_CR33) 2001; 894
MS Green (334_CR46) 2000; 54
M Townsend (334_CR56) 2006; 572
A Alzheimer’s (334_CR1) 2010; 2010
A Poling (334_CR14) 2008; 193
RM Koffie (334_CR18) 2009; 106
MA Deibel (334_CR28) 1996; 143
NL Bjorklund (334_CR63) 2012; 203
334_CR24
MP Lambert (334_CR52) 2007; 100
H Braak (334_CR3) 1991; 82
Y Uchida (334_CR31) 1991; 7
PN Lacor (334_CR51) 2004; 24
AM Grabrucker (334_CR19) 2011; 6
KH Lim (334_CR43) 2007; 46
AI Bush (334_CR45) 1994; 269
KT Dineley (334_CR16) 2010; 88
MA Riudavets (334_CR7) 2007; 28
N Beyer (334_CR30) 2009; 4
SY Assaf (334_CR35) 1984; 308
RJ Cousins (334_CR34) 2006; 281
G Danscher (334_CR27) 1997; 76
TJ Montine (334_CR9) 2012; 123
JP Cleary (334_CR11) 2005; 8
SD O’Shea (334_CR15) 2008; 8
J Naslund (334_CR48) 1994; 91
D Iacono (334_CR8) 2008; 67
AI Bush (334_CR44) 1994; 265
LF Lue (334_CR5) 1999; 155
MA Lovell (334_CR23) 2009; 16
D Religa (334_CR29) 2006; 67
DJ Selkoe (334_CR49) 2002; 298
RA Colvin (334_CR36) 2000; 130
MF Folstein (334_CR61) 1975; 12
SW Suh (334_CR59) 2000; 852
NL Harrison (334_CR38) 1994; 33
JW Karr (334_CR41) 2005; 44
HJ Romijn (334_CR62) 1999; 47
H Bito (334_CR53) 2003; 34
PA Adlard (334_CR32) 2010; 30
NW Alcock (334_CR67) 1987; 13
PN Lacor (334_CR17) 2007; 27
GR Phillips (334_CR50) 2001; 32
D Noy (334_CR25) 2008; 130
J Hardy (334_CR2) 1991; 12
A Deshpande (334_CR26) 2009; 29
AJ Silva (334_CR57) 1998; 21
CC Curtain (334_CR40) 2001; 276
Q Wang (334_CR65) 2005; 19
BKY Bitanihirwe (334_CR54) 2009; 63
PL Kramer (334_CR4) 2011; 32
A Demuro (334_CR13) 2005; 280
CA McLean (334_CR47) 1999; 46
AN Moore (334_CR22) 1996; 271
S-T Liu (334_CR42) 1999; 38
References_xml – volume: 2010
  start-page: 6
  year: 2010
  ident: 334_CR1
  publication-title: Alzheimer’s & Dementia
– volume: 24
  start-page: 10191
  year: 2004
  ident: 334_CR51
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.3432-04.2004
– volume: 34
  start-page: 425
  year: 2003
  ident: 334_CR53
  publication-title: Cell Calcium
  doi: 10.1016/S0143-4160(03)00140-4
– volume: 4
  start-page: 53
  year: 2009
  ident: 334_CR30
  publication-title: Mol Neurodegener
  doi: 10.1186/1750-1326-4-53
– volume: 54
  start-page: 105
  year: 2000
  ident: 334_CR46
  publication-title: Neurology
  doi: 10.1212/WNL.54.1.105
– volume: 27
  start-page: 796
  year: 2007
  ident: 334_CR17
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.3501-06.2007
– volume: 123
  start-page: 605
  year: 2005
  ident: 334_CR58
  publication-title: Histochem Cell Biol
  doi: 10.1007/s00418-005-0787-0
– volume: 47
  start-page: 229
  year: 1999
  ident: 334_CR62
  publication-title: J Histochem Cytochem
  doi: 10.1177/002215549904700211
– volume: 281
  start-page: 24085
  year: 2006
  ident: 334_CR34
  publication-title: J Biol Chem
  doi: 10.1074/jbc.R600011200
– volume: 21
  start-page: 127
  year: 1998
  ident: 334_CR57
  publication-title: Annu Rev Neurosci
  doi: 10.1146/annurev.neuro.21.1.127
– volume: 894
  start-page: 37
  year: 2001
  ident: 334_CR33
  publication-title: Brain Res
  doi: 10.1016/S0006-8993(00)03196-6
– volume: 100
  start-page: 23
  year: 2007
  ident: 334_CR52
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.2006.04157.x
– volume: 130
  start-page: 1376
  year: 2008
  ident: 334_CR25
  publication-title: J Am Chem Soc
  doi: 10.1021/ja076282l
– volume: 32
  start-page: 2113
  year: 2011
  ident: 334_CR4
  publication-title: Neurobiol Aging
  doi: 10.1016/j.neurobiolaging.2010.01.010
– volume: 12
  start-page: 189
  year: 1975
  ident: 334_CR61
  publication-title: J Psychiatr Res
  doi: 10.1016/0022-3956(75)90026-6
– volume: 28
  start-page: 1484
  year: 2007
  ident: 334_CR7
  publication-title: Neurobiol Aging
  doi: 10.1016/j.neurobiolaging.2007.05.005
– volume: 572
  start-page: 477
  year: 2006
  ident: 334_CR56
  publication-title: J Physiol
  doi: 10.1113/jphysiol.2005.103754
– volume: 113
  start-page: 761
  year: 2010
  ident: 334_CR64
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.2010.06643.x
– volume: 111
  start-page: 567
  year: 2006
  ident: 334_CR39
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2005.11.004
– volume: 193
  start-page: 230
  year: 2008
  ident: 334_CR14
  publication-title: Behavioural brain research
  doi: 10.1016/j.bbr.2008.06.001
– volume: 33
  start-page: 935
  year: 1994
  ident: 334_CR38
  publication-title: Neuropharmacology
  doi: 10.1016/0028-3908(94)90152-X
– volume: 67
  start-page: 69
  year: 2006
  ident: 334_CR29
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000223644.08653.b5
– volume: 130
  start-page: 1471S
  year: 2000
  ident: 334_CR55
  publication-title: J Nutr
  doi: 10.1093/jn/130.5.1471S
– volume: 13
  start-page: 363
  year: 1987
  ident: 334_CR67
  publication-title: Biol Trace Elem Res
  doi: 10.1007/BF02796647
– volume: 29
  start-page: 4004
  year: 2009
  ident: 334_CR26
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.5980-08.2009
– volume: 19
  start-page: 869
  year: 2005
  ident: 334_CR65
  publication-title: FASEB J
  doi: 10.1096/fj.04-2370com
– volume: 82
  start-page: 239
  year: 1991
  ident: 334_CR3
  publication-title: Acta Neuropathol
  doi: 10.1007/BF00308809
– volume: 155
  start-page: 853
  year: 1999
  ident: 334_CR5
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)65184-X
– volume: 298
  start-page: 789
  year: 2002
  ident: 334_CR49
  publication-title: Science
  doi: 10.1126/science.1074069
– volume: 276
  start-page: 20466
  year: 2001
  ident: 334_CR40
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M100175200
– volume: 269
  start-page: 12152
  year: 1994
  ident: 334_CR45
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(17)32694-7
– volume: 100
  start-page: 1910
  year: 2011
  ident: 334_CR37
  publication-title: Biophys J
  doi: 10.1016/j.bpj.2011.02.042
– volume: 67
  start-page: 578
  year: 2008
  ident: 334_CR8
  publication-title: J Neuropathol Exp Neurol
  doi: 10.1097/NEN.0b013e3181772794
– volume: 14
  start-page: 837
  year: 2008
  ident: 334_CR20
  publication-title: Nat Med
  doi: 10.1038/nm1782
– volume: 63
  start-page: 1029
  year: 2009
  ident: 334_CR54
  publication-title: Synapse
  doi: 10.1002/syn.20683
– volume: 123
  start-page: 1
  year: 2012
  ident: 334_CR9
  publication-title: Acta Neuropathol
  doi: 10.1007/s00401-011-0910-3
– volume: 440
  start-page: 352
  year: 2006
  ident: 334_CR10
  publication-title: Nature
  doi: 10.1038/nature04533
– volume: 76
  start-page: 53
  year: 1997
  ident: 334_CR27
  publication-title: J Neurosci Methods
  doi: 10.1016/S0165-0270(97)00079-4
– volume: 16
  start-page: 471
  year: 2009
  ident: 334_CR23
  publication-title: J Alzheimer’s Dis
  doi: 10.3233/JAD-2009-0992
– volume: 46
  start-page: 13523
  year: 2007
  ident: 334_CR43
  publication-title: Biochemistry
  doi: 10.1021/bi701112z
– volume: 106
  start-page: 4012
  year: 2009
  ident: 334_CR18
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0811698106
– volume: 271
  start-page: 14214
  year: 1996
  ident: 334_CR22
  publication-title: J Biol Chem
  doi: 10.1074/jbc.271.24.14214
– volume: 30
  start-page: 1631
  year: 2010
  ident: 334_CR32
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.5255-09.2010
– volume: 41
  start-page: 479
  year: 1991
  ident: 334_CR60
  publication-title: Neurology
  doi: 10.1212/WNL.41.4.479
– volume: 7
  start-page: 337
  year: 1991
  ident: 334_CR31
  publication-title: Neuron
  doi: 10.1016/0896-6273(91)90272-2
– volume: 6
  start-page: 65
  year: 2011
  ident: 334_CR19
  publication-title: Mol Neurodegener
  doi: 10.1186/1750-1326-6-65
– volume: 130
  start-page: 1484S
  year: 2000
  ident: 334_CR36
  publication-title: J Nutr
  doi: 10.1093/jn/130.5.1484S
– volume: 265
  start-page: 1464
  year: 1994
  ident: 334_CR44
  publication-title: Science
  doi: 10.1126/science.8073293
– volume: 852
  start-page: 274
  year: 2000
  ident: 334_CR59
  publication-title: Brain Res
  doi: 10.1016/S0006-8993(99)02096-X
– volume: 308
  start-page: 734
  year: 1984
  ident: 334_CR35
  publication-title: Nature
  doi: 10.1038/308734a0
– volume: 88
  start-page: 2923
  year: 2010
  ident: 334_CR16
  publication-title: J Neurosci Res
  doi: 10.1002/jnr.22445
– volume: 32
  start-page: 63
  year: 2001
  ident: 334_CR50
  publication-title: Neuron
  doi: 10.1016/S0896-6273(01)00450-0
– volume: 172
  start-page: 250
  year: 2008
  ident: 334_CR66
  publication-title: J Neurosci Methods
  doi: 10.1016/j.jneumeth.2008.05.003
– ident: 334_CR24
  doi: 10.4061/2011/971021
– volume: 280
  start-page: 17294
  year: 2005
  ident: 334_CR13
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M500997200
– volume: 143
  start-page: 137
  year: 1996
  ident: 334_CR28
  publication-title: J Neurol Sci
  doi: 10.1016/S0022-510X(96)00203-1
– volume: 44
  start-page: 5478
  year: 2005
  ident: 334_CR41
  publication-title: Biochemistry
  doi: 10.1021/bi047611e
– volume: 203
  start-page: 146
  year: 2012
  ident: 334_CR63
  publication-title: J Neurosci Methods
  doi: 10.1016/j.jneumeth.2011.09.008
– volume: 7
  start-page: 824
  year: 2008
  ident: 334_CR12
  publication-title: Aging Cell
  doi: 10.1111/j.1474-9726.2008.00434.x
– volume: 29
  start-page: 12957
  year: 2009
  ident: 334_CR21
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.1064-09.2009
– volume: 8
  start-page: 7428
  year: 2008
  ident: 334_CR15
  publication-title: Sensors
  doi: 10.3390/s8117428
– volume: 8
  start-page: 79
  year: 2005
  ident: 334_CR11
  publication-title: Nat Neurosci
  doi: 10.1038/nn1372
– volume: 46
  start-page: 860
  year: 1999
  ident: 334_CR47
  publication-title: Ann Neurol
  doi: 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M
– volume: 72
  start-page: 354
  year: 2009
  ident: 334_CR6
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000341273.18141.64
– volume: 91
  start-page: 8378
  year: 1994
  ident: 334_CR48
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.91.18.8378
– volume: 38
  start-page: 9373
  year: 1999
  ident: 334_CR42
  publication-title: Biochemistry
  doi: 10.1021/bi990205o
– volume: 12
  start-page: 383
  year: 1991
  ident: 334_CR2
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/0165-6147(91)90609-V
SSID ssj0047005
Score 2.2577424
Snippet Background Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the...
Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers targeting the synapses....
Abstract Background Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional effect of amyloid beta (Aβ) oligomers...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 23
SubjectTerms Aged, 80 and over
Alzheimer Disease - metabolism
Alzheimer Disease - pathology
Alzheimer’s disease
Amyloid beta-Peptides - metabolism
asymptomatic, zinc, synaptic vesicle
Aβ oligomers
Biomedical and Life Sciences
Biomedicine
Blotting, Western
Cognition Disorders - metabolism
Cognition Disorders - pathology
Female
hippocampus
Hippocampus - metabolism
Hippocampus - pathology
Humans
Immunohistochemistry
Male
Molecular Medicine
Neurology
Neurosciences
Research Article
Synapses - metabolism
Synapses - pathology
Zinc - metabolism
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQT1wQUH7CnwYJARKymo0d2zkuiKpCghOVKi6W7dg00jZZNelhOfEanHgHHoSH4EkYO9mIBSouHONY8s-M58cz_oaQJ1YIXzFnqaxcoNwJRU0dFBXcVZWzqHIT2PPbd-LomL85KU9-KfUVc8JGeOBx4w7K0klj8twyW3AX4z6eo9mQS5QYoWYJvTSv8q0zNcpgLvOUvIi6Mafob4kJrnGhxMHcRiUt2I46Sqj9fzM1_8yY_C1smrTR4XVybTIjYTlO_wa54tubZH_Zogt9toGnkBI70435Pvm6tH08v9AFMGfooDc1fP8G3ar52MVbazADoBkI664f-k1r1r0H09ZwPpap9zWkVhwJPrTFC2hamJOOVhv8HIwbAOVSDc38vKuHeMMLy9WnU9_gKD8-f-lhigZBAtGMtZDTDG-R48PX718d0akuA3WozwfK4vvcUnprFibkrKjRjanim_GAuyo9UlipYJgxrkSDUdacMxSiCyvLEDz-YLfJXtu1_i4Br1yQPEYfK8uDMEpZtDgWlStUaRfeZIRuyaPdBFoea2esdHJelNCRnDqSU0tdsIw8m_uvR7iOS3u-jNSee0WY7dSAzKcn5tP_Yr6MPN7yisZjGWMtpvXdRa-j3YbCTqgqI3dG3pmHim-XYzpSRuQOV-3MZfdP25wm6G_Gc1YpHPf5lv_0JHP6S9Z573-s8z65ioZiEbMmCvWA7A3nF_4hGmODfZTO3U_SCTP0
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELagXLggoPyEPw0SAiRkkcSO7RyXFVWFBCcqVVws27FppG2yatLDcuI1OPEOPAgPwZMw9mZXLKUSx9iO7GTGM994fkzIMyuEr5mzVNYuUO6EoqYJigru6tpZVLmp2PP7D-LwiL87ro6nANmYC_On_75Q4jVqt5yixSSopCW7Sq5VKHQjJ8_FfCNxuURWmgoyXnxnR-Gkuvz_ApMXYyL_cowmfXNwk9yYgCLM1pS9Ra747jbZn3VoJJ-u4Dmk0M10Jr5Pvs_sEHco9AHMKZrgbQM_f0C_aD_38VwazAgI9GDZD-Ow6sxy8GC6Bs7WF9H7BlIrzgSfuvIVtB1sw4oWK3wcjRsBJU8D7TaBa4B4hguzxZcT3-Isv75-G2Dy90AqkxlvO04rvEOODt5-nB_S6eYF6lBjj5TFDNxKemsKE3JWNmio1DErPOBflR5pqFQwzBhXISSUDecMxWRhZRWCxw52l-x1fefvE_DKBcmjf7G2PAijlEVMUdSuVJUtvMkI3ZBHu6ksebwdY6GTeaKEjuTUkZxa6pJl5MV2_HJdkOPSkW8itbejYiHt1ID8pad9qavKSWPy3DJbchfdip4jKs0lKqTQsCojTze8onHjRW-K6Xx_PuiIzFCcCVVn5N6ad7ZTxezkGHCUEbnDVTtr2e3p2pNU3JvxnNUK53254T89SZXhku988P9DH5LrCPjKGP1Qqkdkbzw7948RVI32SdpRvwERiiB0
  priority: 102
  providerName: Springer Nature
Title Absence of amyloid β oligomers at the postsynapse and regulated synaptic Zn2+ in cognitively intact aged individuals with Alzheimer’s disease neuropathology
URI https://link.springer.com/article/10.1186/1750-1326-7-23
https://www.ncbi.nlm.nih.gov/pubmed/22640423
https://www.proquest.com/docview/1028017689
https://pubmed.ncbi.nlm.nih.gov/PMC3403985
https://doaj.org/article/55c7aa00b3b24c1281e408307eacfd35
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELZoe-GCgPKTAqtBQoCEAtnYiZ0DQumqVbUSFQJWWnGJbMdpI22TZZNKLCdegxPvwIPwEDwJY282aGkrcYriOHLimfF84xnPEPJExbFJqFY-T3ThMx0LX-aF8GOmk0QrVLku2fPb4_howsbTaPo3_qmbwOZS087Wk5osZi-_fF6-QYF_7QRexK9QAwY-WlWxz_2QbpEd5yuyYXys9ygwHrhwxr5vl8Dx4vsbCsrl8b8MfF6MofzHker00-FNcqMDlpCuOOEWuWaq22Q3rdCoPlvCU3Chnm4PfZf8SFVjJRrqAuQZmuxlDr9-Qj0rT2q7jw2yBQSGMK-btllWct4YkFUOi1XhepODa8WR4FMVvoCygj4MabbE21bqFnClyqHsD3w1YPd8IZ19PTUljvL72_cGOv8QuLSatjqy-8I7ZHJ48HF05HeVGnyNGr71qT2xG3Gj5FAWAQ1zNGwSe4q8wFnlBmkuRCGplDpCCMlzxiguq0PFo6Iw-IDeJdtVXZn7BIzQBWfWH5koVsRSCIUYZJjoUERqaKRH_DV5Mt2lMbfVNGaZM2dEnFlyZpacGc9C6pFnff_5KoHHlT33LbX7XjbxtmuoFydZJ8dZFGkuZRAoqkKmrRvSMESxAUcFVuQ08sjjNa9kKKjW-yIrU583mUVyuPzFIvHIvRXv9EPZ08w2QMkjfIOrNr5l80lVnrpk4JQFNBE47vM1_2VrIbriP_f-e0YekOuID0MbLBGKh2S7XZybR4jBWjUgW3zKB2QnTccfxnjdPzh-9x5bR_Fo4PY1Bk78_gC_fTZC
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELagHOCCgPKz_A4SAiQUNYkd2zkuK6oF2p5aqeJi2Y5NI22TVZMelhOvwYl34EF4CJ6EsTe7YimVOCZx5OzOeOYbz8xnQl4Yzl1JrUlEaX3CLJeJrrxMOLNlaQ263Ej2vH_Ap0fsw3FxPBTIhl6YP_P3meQ76N3SBCMmnogkp1fJtZC1DBz5Ez5ZWVwmUJUGQsaL72w4nMjL_y8webEm8q_EaPQ3u7fIzQEowngp2dvkimvukO1xg0Hy6QJeQizdjHvi2-T72HRhhULrQZ9iCF5X8PMHtLP6cxv2pUH3gEAP5m3Xd4tGzzsHuqngbHkQvasg3sWZ4FOTv4G6gXVZ0WyBl722PaDlqaBeN3B1EPZwYTz7cuJqnOXX128dDPkeiDSZ4bTj-IV3ydHuu8PJNBlOXkgseuw-oaEDtxDO6Ez7lOYVBipl6Ar3-K8KhzKU0muqtS0QEoqKMYpmMjOi8N7hA3qPbDVt4x4QcNJ6wUJ-sTTMcy2lQUyRlTaXhcmcHpFkJR5lB1rycDrGTMXwRHIVxKmCOJVQOR2RV-vx8yUhx6Uj3wZpr0cFIu14A_VLDetSFYUVWqepoSZnNqQVHUNUmgp0SL6ixYg8X-mKwoUXsim6ce15pwIyQ3PGZTki95e6s54qdCeHgqMRERtatfEtm0-a-iSSe1OW0lLivK9X-qcGq9Jd8jsf_v_QZ-T69HB_T-29P_j4iNxA8JeHSohcPiZb_dm5e4IAqzdP4-r6DcouI2M
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELZKKyEuqFCgS_kZJARIKGo2TmJH4hJ-VmWBCgkqVVws27HbSNtktUkPy4nX4MQ78CA8BE_C2ElWWkoljnEcOcn8e2Y-E_JYpanJqFYBy7QNYp3yQBaWB2mss0wrNLke7PnDYXpwFE-Pk-MN8mLohfHV7kNKsutpcChNVbs_L2wn4jzdR5sXBhhHpQELInqFbPEkyzD02srz6afpoIljhizWAzVefGrNEHm8_n85mRdrJf9KmHo7NNkm13sHEvKO4jfIhqlukp28wuD5bAlPwJd0-r3yHfIjV42TXKgtyDMMzcsCfv2Eelae1G6_GmQL6ADCvG7aZlnJeWNAVgUsugPqTQF-FFeCL1X0HMoKVuVGsyVetlK3gBqpgHLV2NWA29uFfPb11JS4yu9v3xvo80Dg4TPdKcj-DW-Ro8mbz68Ogv5EhkCjJW8D6jpzE2aUHEsb0qjAACZz3eIW_yozSFvOraRS6gRdRVbEMUX1OVYssdbgDXqbbFZ1ZXYJGK4ti13eMVOxTSXnCn2NcaYjnqixkSMSDOQRuocrd6dmzIQPW3gqHDmFI6dgIqIj8nQ1f94BdVw686Wj9mqWA9j2A_XiRPTyKpJEMynDUFEVxdqlG02M3mrI0FDZgiYj8mjgFYEC6bIssjL1eSOcx4ZqLuXZiNzpeGe1lOtadoVII8LWuGrtXdbvVOWpB_2mcUgzjus-G_hP9NqmueQ77_7_1Ifk6sfXE_H-7eG7PXINfcLIFUhE_B7ZbBfn5j76Xa160IvXHyw_LSE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Absence+of+amyloid+%CE%B2+oligomers+at+the+postsynapse+and+regulated+synaptic+Zn2%2B+in+cognitively+intact+aged+individuals+with+Alzheimer%E2%80%99s+disease+neuropathology&rft.jtitle=Molecular+neurodegeneration&rft.au=Bjorklund%2C+Nicole+L&rft.au=Reese%2C+Lindsay+C&rft.au=Sadagoparamanujam%2C+V-M&rft.au=Ghirardi%2C+Valeria&rft.date=2012-05-28&rft.issn=1750-1326&rft.eissn=1750-1326&rft.volume=7&rft.issue=1&rft_id=info:doi/10.1186%2F1750-1326-7-23&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_1750_1326_7_23
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1326&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1326&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1326&client=summon